Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Review, H2 2016’, provides an overview of the Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections

The report reviews pipeline therapeutics for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections therapeutics and enlists all their major and minor projects

The report assesses Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allergan Plc

Galapagos NV

Merck & Co Inc

Syntiron LLC

Valevia UK Ltd

Allergan Plc

Galapagos NV

Merck & Co Inc

Syntiron LLC

Valevia UK Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Community Acquired ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections Overview 6

Therapeutics Development 7

Pipeline Products for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Overview 7

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Therapeutics under Development by Companies 8

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Products under Development by Companies 11

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Companies Involved in Therapeutics Development 12

Allergan Plc 12

Galapagos NV 13

Merck & Co Inc 14

Syntiron LLC 15

Valevia UK Ltd 16

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Drug Profiles 26

acorafloxacin hydrochloride - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

GLPG-1492 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

solithromycin - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Staphylococcus aureus vaccine - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

VAL-301 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Dormant Projects 43

Appendix 44

Methodology 44

Coverage 44

Secondary Research 44

Primary Research 44

Expert Panel Validation 44

Contact Us 44

Disclaimer 45

List of Tables

List of Tables

Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections, H2 2016 7

Number of Products under Development by ...

List of Tables

Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Allergan Plc, H2 2016 12

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Galapagos NV, H2 2016 13

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Merck & Co Inc, H2 2016 14

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Syntiron LLC, H2 2016 15

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Valevia UK Ltd, H2 2016 16

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Stage and Target, H2 2016 19

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 25

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Dormant Projects, H2 2016 43

List of Figures

List of Figures

Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections, H2 2016 7

Number of Products under Development by ...

List of Figures

Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Targets, H2 2016 18

Number of Products by Stage and Targets, H2 2016 18

Number of Products by Mechanism of Actions, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 20

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Molecule Types, H2 2016 24

Number of Products by Stage and Molecule Types, H2 2016 24

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports